In stage IV NSCLC patients treated with atezolizumab, EGFR focal amplification—often associated with resistance to EGFR-TKI therapy—may indicate a tumor phenotype less responsive to PD-L1 blockade [15]. Here, EGFR is linked to neoplasm.